Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus (Q42277527)

19 October 2017

title

Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus (English)

1 reference

19 October 2017

7

E De Clercq

0 references

Robert Snoeck

object named as

R Snoeck

2

0 references

Graciela Andrei

object named as

G Andrei

1

0 references

author name string

D Reymen

3

1 reference

19 October 2017

C Liesnard

4

1 reference

19 October 2017

P Goubau

5

1 reference

19 October 2017

J Desmyter

6

1 reference

19 October 2017

E De Clercq

7

1 reference

19 October 2017

publication date

1 April 1995

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

19 October 2017

published in

1 reference

19 October 2017

volume

14

1 reference

19 October 2017

issue

4

1 reference

19 October 2017

page(s)

318-329

1 reference

Acyclovir prevents dissemination of varicella in immunocompromised children.

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Therapeutic approaches to varicella-zoster virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Treatment of Varicella-Zoster Virus Infections with Adenine Arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Foscarnet Therapy in Five Patients with AIDS and Acyclovir-resistant Varicella-Zoster Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Antiviral activity of oxetanocins against varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02116525

Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.

21 January 2018

1 reference

12 December 2020

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

1 reference

12 December 2020

(+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses

1 reference

12 December 2020

Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus

1 reference

12 December 2020

Oral acyclovir to prevent dissemination of varicella in immunocompromised children

1 reference

12 December 2020

Herpes zoster: pathogenesis and latency

1 reference

12 December 2020

Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster virus strains

1 reference

12 December 2020

Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis

1 reference

12 December 2020

Flow cytometric method for the detection of gpI antigens of varicella zoster virus and evaluation of anti-VZV agents

1 reference

12 December 2020

A novel selective broad-spectrum anti-DNA virus agent

1 reference

12 December 2020

Acyclovir: A Decade Later

1 reference

12 December 2020

A double-blind clinical study in patients with herpes zoster to establish YN-72 (Brovavir) dose

1 reference

12 December 2020

Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy.

1 reference

12 December 2020

Acyclovir-resistant varicella zoster responsive to foscarnet.

1 reference

12 December 2020

Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial

1 reference

12 December 2020

In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against newly isolated clinical varicella-zoster virus strains

1 reference

12 December 2020

Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group

1 reference

12 December 2020

Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient

1 reference

12 December 2020

Clinical effect of BV-araU on varicella-zoster virus infection in immunocompromised patients with haematological malignancies

1 reference

12 December 2020

2'-Fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: efficacy in immunosuppressed individuals with herpes zoster

1 reference

12 December 2020

Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine

1 reference

12 December 2020

Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment

1 reference

12 December 2020

Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine

1 reference

12 December 2020

Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS

1 reference

12 December 2020

Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

1 reference

12 December 2020

Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on varicella-zoster virus replication in cell culture

1 reference

12 December 2020

Vidarabine therapy of varicella in immunosuppressed patients

1 reference

12 December 2020

Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys

1 reference

12 December 2020

Chemotherapy of varicella zoster virus infections.

1 reference

12 December 2020

5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication

1 reference

12 December 2020

Varicella and herpes zoster: a perspective and overview

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02116525

1 reference

Dimensions Publication ID

19 October 2017

1025102670

0 references

1 reference